A case of JAK2 positive essential thrombocythemia 16.5 years after autologous marrow transplantation for AML [1]

Bone Marrow Transplantation

Volumn 39, Issue 11, 2007, Pages 725-726

  Walker, A R ^a   Rothberg, P G ^a   Liesveld, J L ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; JANUS KINASE 2; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD ANALYSIS; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENETIC CODE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; LEUKOPENIA; MONOTHERAPY; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; POINT MUTATION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTHEMIA; THROMBOCYTOPENIA;

ACUTE DISEASE; ADULT; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID; MIDDLE AGED; POINT MUTATION; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 34249301746     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705647     Document Type: Letter

References (5)

1. Negrin R, Blume K. Principles of hematopoietic cell transplantation. In: Lichtman MA (ed). Williams Hematology. The McGraw-Hill Companies Inc: New York, 2006, pp 301-322.
2. V617F mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208-213.
3. Lee J, Kim Y, Soung Y, Han K, Kim S, Rhim H et al. The JAK2 V617 mutation in de novo acute myelogenous leukemias. Oncogene 2006; 25: 1434-1436.
4. Levine RL, Loriaux M, Huntly BJ, Loh M, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-3379.
5. Sidon P, El Housni H, Dessars B, Heimann P. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006; 20: 1622.